OFFICIAL

Ministerial Submission – Standard MS19-001103 Version (1) Date sent to MO:13/09/19

To: Minister Hunt

s22

Subject: POLICY APPROVAL AND EXPENDITURE APPROVAL FOR MEDICAL RESEARCH FUTURE FUND (MRFF) - EMERGING PRIORITIES AND CONSUMER DRIVEN RESEARCH (EPCDR) INVESTMENT

PLAN (2019-20 TO 2023-24)

Critical date: 20 September 2019 to enable 2019-20 Grant Opportunities to progress in a timely

manner.

OCUMENT HAS BEEN AND AGED CARRE

FOI 4315

Contact
Officer:
Clearance
Offic

-22

OFFICIAL

- 4. The Department recommends option b) as it would enable greater transparency and opportunity for a variety of stakeholders to submit applications to be assessed and peer reviewed with grants awarded on merit. This option would be the least resource intensive and most cost effective option for the Department.
 - Option c would increase transparency in funding allocation for this initiatives at the same time as providing you discretion to allocate funds to emerging priorities and consumer initiative activities.



Sensitivities:

PCDRI Factor No. 1987 CHILD CARRETTE OF THE PORT OF TH Accelerated Research investments (now called EPCDR) have received criticism in the past for a lack of contestability. This sensitivity can be mitigated by highlighting that the EPCDR Initiative now consists of multiple open and closed grant rounds with a focus on collaboration between consumers and researchers in addressing unmet need and emerging priorities. Recipients are also asked to comply with the Government endorsed MRFF Funding Principles where appropriate.

FOI 4315 Document 1



OFFICIAL

Ministerial Submission – Standard MS20-000326 Version (1) Date sent to MO:20/03/2020

To: Minister Hunt

Subject: Policy Approval and Approval in Principle for expenditure of \$3.35 million from

the Medical Research Future Fund (MRFF) Coronavirus Research Response for

COVID-19 vaccine research and clinical trials

s22

Contact Dr Masha Somi Chief Executive Officer
Officer: Health and Medical Research Office Mobile: S22
Clearance Paul McBride First Assistant Secretary Ph: (02) 6289 8469
Officer: Health Economics and Research Division Mobile:

s22

THE PREED ON DEPARTMENT OF HEALTH AND ACTOR OF THE PREED OF THE PREED

Sensitivities:

The Department understands that a COVID-19 vaccines are being developed by Australian research groups other than the University of Queensland. There is a possibility that allocating funds directly to the University of Queensland outside of the open, competitive MRFF grant opportunity process currently in train could be criticised by stakeholders, particularly those participating in that process.

s22

The Department and your Office have received a number of unsolicited research proposals and requests for funding into COVID-19 research. Whereever possible, these approaches are being referred to the Coronavirus Research Response package, with encouragement to apply for open, competitive grant opportunities via GrantConnect.

s22

THE PREED ON DEPARTMENT OF HEALTH AND ACTOR OF THE PREED OF THE PREED